LIPTRUZET
Clinical safety rating
cautionComprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).
Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).
Primary hyperlipidemiaHomozygous familial hypercholesterolemiaHomozygous sitosterolemia (ezetimibe component)
Ezetimibe inhibits intestinal cholesterol absorption at the brush border of the small intestine, while simvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis; combination lowers plasma LDL-C.
| Metabolism | Ezetimibe: glucuronidation (UGT1A1, UGT1A3, UGT2B15); simvastatin: CYP3A4 (primary), CYP3A5; both undergo extensive first-pass metabolism. |
| Excretion | Rosuvastatin: 90% fecal, 10% renal. Ezetimibe: 78% fecal as unchanged drug, 11% renal as glucuronide conjugate. |
| Half-life | Rosuvastatin: 19 hours. Ezetimibe: 22 hours for ezetimibe-glucuronide. Allows once-daily dosing. |
| Protein binding | Rosuvastatin: 88% bound to albumin. Ezetimibe: >90% bound to albumin. |
| Volume of Distribution | Rosuvastatin: 1.1 L/kg. Ezetimibe: 5.8 L/kg (apparent) due to extensive enterohepatic recirculation. |
| Bioavailability | Rosuvastatin: 20% oral. Ezetimibe: 35-65% unknown absolute; systemic exposure increased with food. |
| Onset of Action | Oral: LDL-C reduction begins within 1 week, maximal by 4 weeks. |
| Duration of Action | Duration of lipid-lowering effect persists with continued daily dosing; steady state achieved by 2 weeks for rosuvastatin and 3-4 weeks for ezetimibe. |
| Molecular Weight | 326.44 |
Lipoprotein(a) apheresis is performed at a flow rate of 1-2 mL/min for 60-90 minutes, repeated every 2-4 weeks. For atorvastatin component: initiate at 10-20 mg orally once daily, titrate up to 80 mg once daily based on response.
| Dosage form | TABLET |
| Renal impairment | Atorvastatin: no adjustment required in mild to moderate renal impairment; avoid CrCl <30 mL/min. Lipoprotein(a) apheresis: no renal adjustment needed. |
| Liver impairment | Atorvastatin: contraindicated in active liver disease or unexplained ALT/AST >3x ULN. Child-Pugh Class A: no dose adjustment; Class B: use with caution; Class C: contraindicated. Lipoprotein(a) apheresis: no hepatic adjustment. |
| Pediatric use | Atorvastatin: children ≥10 years: 10 mg orally once daily, max 20 mg once daily. Lipoprotein(a) apheresis: not established in pediatric population. |
| Geriatric use | Atorvastatin: start at lower initial dose (10 mg) due to increased risk of myopathy; titrate cautiously. Lipoprotein(a) apheresis: no specific dose adjustment, but consider tolerance to extracorporeal volume. |
| 1st trimester | Contraindicated due to risk of skeletal and visceral malformations; neural tube defects and cardiac anomalies reported. |
| 2nd trimester | Contraindicated; continued exposure may cause fetal intracranial hypertension and skeletal abnormalities. |
| 3rd trimester | Contraindicated; associated with premature epiphyseal closure and cranial nerve deficits. |
Clinical note
Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).
| Placental transfer | Acitretin crosses the placenta extensively; fetal plasma concentrations are approximately 50-60% of maternal levels. Teratogenicity is well-documented. |
| Breastfeeding | LIPTRUZET (acitretin) is excreted in human milk; due to potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during treatment and for at least 2 years after discontinuation. |
| Lactation Rating | L5 |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of severe fetal cardiac defects, orofacial clefts, neural tube defects. Second and third trimesters: risk of fetal renal anomalies, oligohydramnios, premature closure of ductus arteriosus. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, serum electrolytes. Fetal ultrasound for renal anomalies and amniotic fluid volume. Weekly nonstress test after 32 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; reduced sperm count and motility. No direct effect on female fertility in animal studies. |
■ FDA Black Box Warning
Simvastatin component: increased risk of myopathy/rhabdomyolysis when used with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone); contraindicated with such drugs; also contraindicated with gemfibrozil, cyclosporine, danazol.
| Serious Effects |
Pregnancy or women of childbearing potential not using two effective forms of contraceptionBreastfeedingSevere hepatic impairmentSevere renal impairmentHypersensitivity to acitretin or any excipients
| Precautions | Myopathy/rhabdomyolysis risk; hepatic enzyme elevations; contraindicated with strong CYP3A4 inhibitors; pregnancy category X; avoid heavy alcohol use; monitor liver function before and after initiation; caution in patients with predisposing factors for myopathy. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing atorvastatin levels and risk of myopathy/rhabdomyolysis. No other significant food interactions; take without regard to meals. |
| Clinical Pearls | LIPTRUZET (ezetimibe/atorvastatin) is a fixed-dose combination for primary hyperlipidemia and mixed dyslipidemia. Start at the lowest available dose (10/10 mg) and titrate based on LDL-C response. Monitor hepatic transaminases and CPK; discontinue if myopathy suspected. Avoid in active liver disease or unexplained persistent transaminase elevation. Pregnancy category X. |
| Patient Advice | Take exactly as prescribed, usually once daily at any time with or without food. · Swallow whole; do not crush, chew, or break tablets. · Report unexplained muscle pain, tenderness, or weakness, especially with fever or malaise. · Avoid grapefruit and grapefruit juice during treatment. · Inform your doctor of all medications, especially other lipid-lowering agents, antifungals, macrolide antibiotics, and anticoagulants. · Pregnancy and breastfeeding: Do not use; effective contraception is required if of childbearing potential. |
Loading safety data…